SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Tá CART-ddBCMA á imscrúdú faoi láthair i dtriail ríthábhachtach Chéim 2, agus is é CART-ddBCMA teiripe T-chealla Arcellx a úsáideann ceanglóir sintéiseach nua na cuideachta, an D-Domain. Déanfaidh Kite agus Arcellx sócmhainn CART-ddBCMA sna SA a chur chun cinn agus a thráchtálú i gcomhpháirt, agus déanfaidh Kite an táirge a thráchtálú lasmuigh de SAM.
Teiripe CAR T-Cell i measc na cóireála cinn do chineálacha áirithe ailsí fola. Tá níos mó ná 750 ar siúl trialacha cliniciúla in Teiripe CAR T-Cell sa tSín faoi láthair. Is féidir le hothair ar mian leo clárú dul i dteagmháil AilseFax líne chabhrach othar ar WhatsApp + 91 96 1588 1588 nó ríomhphost chuig eolas@cancerfax.com.
Maidir le Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory il-mhóilíní (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk siondróm myelodysplastic, initiated in the fourth quarter of 2022.
Maidir leis an Eitleog
Is cuideachta bhithchógaisíochta domhanda é Kite, Cuideachta Gilead, atá lonnaithe i Santa Monica, California, atá dírithe ar theiripe cille chun ailse a chóireáil agus a d’fhéadfadh a bheith ann a leigheas. Mar cheannaire domhanda teiripe cille, tá cóireáil déanta ag Kite ar níos mó othar le teiripe T-chealla CAR ná aon chuideachta eile. Tá an líonra déantúsaíochta teiripe cille intí is mó ar domhan ag Kite, a chuimsíonn forbairt próisis, déantúsaíocht veicteora, soláthar trialach cliniciúla, agus déantúsaíocht táirgí tráchtála.
Maidir le hEolaíochtaí Gilead
Is cuideachta bhithchógaisíochta é Gilead Sciences, Inc. atá tar éis dul chun cinn sa leigheas a shaothrú agus a bhaint amach le breis agus tríocha bliain anuas, agus é mar sprioc aige domhan níos sláintiúla a chruthú do gach duine. Tá an chuideachta tiomanta do chógais nuálaíocha a chur chun cinn chun galair atá bagrach don bheatha a chosc agus a chóireáil, lena n-áirítear VEID, heipitíteas víreasach agus ailse. Feidhmíonn Gilead i níos mó ná 35 tír ar fud an domhain, le ceanncheathrú i Foster City, California. Ghnóthaigh Gilead Sciences Kite in 2017.
